In one patient, a tumor lysis syndrome occurred after the first dose of tebentafusp—including a decrease in prothrombin time and highly elevated LDH, C-reactive protein, uric acid and creatinine in serum. This evidence concerns the gene F2 and Tumor Lysis Syndrome.